Table 2.
Apoptosis genes associated with disease-free survival in pediatric ALL
| Gene name | Probe set ID | Outcome |
|---|---|---|
| BAG1 | 211475_s_at | 0.91 |
| BAG1 | 202387_at | 0.81 |
| BAG5 | 202895_s_at | 1.26* |
| BAG5 | 202984_s_at | 1.20* |
| BCL2L13 | 217955_at | 0.72* |
| BID | 204493_at | 0.87 |
| BIK | 205780_at | 0.25* |
| XIAP | 206537_at | 1.30 |
| CASP9 | 203984_s_at | 0.79 |
| CYCS | 208905_at | 0.83 |
| PECAM-1 | 208982_at | 1.33 |
| PECAM-1 | 208981_at | 1.66 |
| CASP1 | 211367_s_at | 0.77 |
| FAS | 216252_x_at | 0.99 |
| TRAIL-R2 | 210405_x_at | 1.73 |
| TRAIL-R2 | 209295_at | 1.36 |
| TRAIL-R4 | 210654_at | 1.53 |
The global test and Wilcoxon rank-sum test with FDR controlled at 5% were performed to identify which of the 118 apoptosis probe sets under study were differentially expressed in leukemic cells taken at initial diagnosis of ALL from patients who achieved and remained in continuous complete remission (CCR) and patients who achieved a complete remission but relapsed during or after completion of chemotherapy. Probe sets selected only by the global test (P < .001).
*
Probe sets selected by the global test and Wilcoxon rank-sum test with FDR less than 5%.